# KLF13

## Overview
KLF13, or Krüppel-like factor 13, is a gene that encodes the KLF transcription factor 13, a member of the Krüppel-like factor family of transcription factors. This protein is characterized by its three C2H2 zinc finger domains, which facilitate its binding to specific DNA sequences, thereby regulating gene expression (Nagashima2009Molecular; Song2002Functional). KLF13 plays a crucial role in various biological processes, including cardiac development, immune response, and neuronal protection, by modulating the expression of target genes through its interactions with other proteins and co-repressors (ÁvilaMendoza2023KLF13; Zhou2007KrüppelLike). Clinically, mutations in the KLF13 gene have been associated with congenital heart diseases, highlighting its significance in cardiogenesis and its potential as a genetic modifier in related pathologies (Darwich2017KLF13; Li2020Identification).

## Structure
KLF13, a member of the Krüppel-like factor family, is characterized by a molecular structure that includes three C2H2 zinc finger domains located at the C-terminus, which are crucial for DNA binding (Nagashima2009Molecular; Song2002Functional). These zinc fingers bind to GC-rich sequences and linked GT and CACCC boxes, facilitating the protein's role as a transcription factor (Khan2022Determining). The primary structure of KLF13 consists of 288 amino acids, with specific domains contributing to its function. The N-terminal region contains a Sin3A-binding domain, which is essential for its interaction with the co-repressor Sin3A, playing a significant role in transcriptional repression (Nagashima2009Molecular; Khan2022Determining).

The protein also features distinct transcriptional activation and repression domains. The activation domain is located at the amino terminus (amino acids 1-35), while the repression domain spans amino acids 67-168 (Song2002Functional). KLF13 contains two independent nuclear localization signals, one upstream of the zinc finger domain and another within the zinc fingers, ensuring its nuclear translocation (Song2002Functional). The interaction with Sin3A involves both hydrogen bonding and hydrophobic interactions, with hydrophobic interactions being more significant (Khan2022Determining). These structural features enable KLF13 to function effectively as a transcription regulator, influencing gene expression related to KRAS signaling pathways (Khan2022Determining).

## Function
KLF13, a member of the Krüppel-like factor family, functions primarily as a transcriptional regulator in various cellular processes. In the context of the JAK/STAT signaling pathway, KLF13 plays a dual role by inhibiting STAT3 activity while promoting STAT5 activity. This regulation is crucial for maintaining the balance of the pathway, particularly in response to growth hormone (GH) stimulation. KLF13 achieves this by associating with the promoters of genes such as Jak1, Stat5b, Socs1, and Socs3, modulating their expression levels (ÁvilaMendoza2023KLF13).

In neuronal cells, KLF13 acts as a transcriptional repressor, impacting the expression of numerous genes involved in cell cycle regulation, cell survival, and synaptic function. It has been shown to protect neurons from excitotoxicity and promote cell viability, suggesting a cytoprotective role (ÁvilaMendoza2020Molecular). KLF13 also influences the expression of neurotrophic factors like IGF1 and BDNF, which are important for neuroprotection and neurotrophic effects in the central nervous system (ÁvilaMendoza2023KLF13).

In T lymphocytes, KLF13 regulates the expression of the chemokine RANTES and the anti-apoptotic factor BCL-X L, thereby influencing immune responses and cell survival (Zhou2007KrüppelLike).

## Clinical Significance
Mutations in the KLF13 gene have been implicated in various congenital heart diseases (CHD). The S156N and P163S variants of KLF13 have been studied for their effects on protein expression and interaction with TBX5, a cofactor in cardiac cells. The S156N variant is a gain-of-function mutation that enhances KLF13's role in cardiogenesis, while the P163S variant is a loss-of-function mutation that impairs it (Li2020Identification). Another mutation, NM_015995.3: c.430G>T; p.(Glu144*), was identified in patients with patent ductus arteriosus, ventricular septal defect, and bicuspid aortic valve. This mutation disrupts the transcriptional activation of downstream genes and nullifies the synergistic interaction between KLF13 and TBX5, contributing to CHD (Abhinav2022A).

KLF13 also acts as a genetic modifier of the TBX5 gene, which is associated with Holt-Oram Syndrome and CHD. Alterations in KLF13 expression or mutations can lead to increased penetrance of congenital heart defects, such as atrial and ventricular septal defects, particularly when interacting with TBX5 mutations (Darwich2017KLF13). These findings underscore the clinical significance of KLF13 in heart development and its potential role in CHD pathogenesis.

## Interactions
KLF13 interacts with several proteins and nucleic acids, playing a significant role in various biological processes. It forms a complex with the co-repressor Sin3A, which is crucial for transcription repression in prostate cancer. This interaction involves a specific binding domain at the N-terminus of KLF13 and is stabilized by hydrogen bonds and hydrophobic interactions (Khan2022Determining). KLF13 also interacts with HDAC1, another co-repressor, to suppress TGF-β-response genes in kidney tubular epithelial cells (Simmen2023Krüppellike).

In cardiac development, KLF13 interacts with TBX5, a transcription factor, to synergistically activate cardiac promoters. This interaction is mediated by the last two zinc fingers of KLF13 and the T-box domain of TBX5, highlighting its role in cardiac gene expression (Darwich2017KLF13). KLF13 also interacts with CBP and PCAF, which modulate its transcriptional activity through acetylation, and with PRP4, which phosphorylates KLF13, affecting its DNA binding affinity (Simmen2023Krüppellike).

KLF13's interaction with the AKT signaling pathway is significant in prostate cancer, where it inhibits AKT activation, leading to apoptosis and reduced cell proliferation (Wang2018Transcription). These interactions underscore KLF13's multifaceted role in transcriptional regulation and its potential involvement in oncogenesis and cardiac development.


## References


[1. (Nagashima2009Molecular) Toshio Nagashima, Fumiaki Hayashi, Takashi Umehara, and Shigeyuki Yokoyama. Molecular Structures of Krüppel-like Factors, pages 21–31. Springer Japan, 2009. URL: http://dx.doi.org/10.1007/978-4-431-87775-2_2, doi:10.1007/978-4-431-87775-2_2. This article has 1 citations.](https://doi.org/10.1007/978-4-431-87775-2_2)

[2. (ÁvilaMendoza2023KLF13) José Ávila-Mendoza, Karen Delgado-Rueda, Valeria A. Urban-Sosa, Martha Carranza, Maricela Luna, Carlos G. Martínez-Moreno, and Carlos Arámburo. Klf13 regulates the activity of the gh-induced jak/stat signaling by targeting genes involved in the pathway. International Journal of Molecular Sciences, 24(13):11187, July 2023. URL: http://dx.doi.org/10.3390/ijms241311187, doi:10.3390/ijms241311187. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241311187)

3. (Khan2022Determining) Determining KLF13 structure, uniqueness, and possible molecular crosstalk in Prostate Cancer. This article has 1 citations.

[4. (Abhinav2022A) Pradhan Abhinav, Gao-Feng Zhang, Cui-Mei Zhao, Ying-Jia Xu, Juan Wang, and Yi-Qing Yang. A novel klf13 mutation underlying congenital patent ductus arteriosus and ventricular septal defect, as well as bicuspid aortic valve. Experimental and Therapeutic Medicine, March 2022. URL: http://dx.doi.org/10.3892/etm.2022.11240, doi:10.3892/etm.2022.11240. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2022.11240)

[5. (Song2002Functional) An Song, Anita Patel, Kimberlee Thamatrakoln, Chian Liu, Dongdong Feng, Carol Clayberger, and Alan M. Krensky. Functional domains and dna-binding sequences of rflat-1/klf13, a krüppel-like transcription factor of activated t lymphocytes. Journal of Biological Chemistry, 277(33):30055–30065, August 2002. URL: http://dx.doi.org/10.1074/jbc.M204278200, doi:10.1074/jbc.m204278200. This article has 79 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M204278200)

[6. (Li2020Identification) Wenjuan Li, Baolei Li, Tingting Li, Ergeng Zhang, Qingjie Wang, Sun Chen, and Kun Sun. Identification and analysis of klf13 variants in patients with congenital heart disease. BMC Medical Genetics, April 2020. URL: http://dx.doi.org/10.1186/s12881-020-01009-x, doi:10.1186/s12881-020-01009-x. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12881-020-01009-x)

[7. (Zhou2007KrüppelLike) Meixia Zhou, Lisa McPherson, Dongdong Feng, An Song, Chen Dong, Shu-Chen Lyu, Lu Zhou, Xiaoyan Shi, Yong-Tae Ahn, Demin Wang, Carol Clayberger, and Alan M. Krensky. Krüppel-like transcription factor 13 regulates t lymphocyte survival in vivo. The Journal of Immunology, 178(9):5496–5504, May 2007. URL: http://dx.doi.org/10.4049/jimmunol.178.9.5496, doi:10.4049/jimmunol.178.9.5496. This article has 50 citations.](https://doi.org/10.4049/jimmunol.178.9.5496)

[8. (Darwich2017KLF13) Rami Darwich, Wenjuan Li, Abir Yamak, Hiba Komati, Gregor Andelfinger, Kun Sun, and Mona Nemer. Klf13 is a genetic modifier of the holt-oram syndrome gene tbx5. Human Molecular Genetics, 26(5):942–954, January 2017. URL: http://dx.doi.org/10.1093/hmg/ddx009, doi:10.1093/hmg/ddx009. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddx009)

[9. (ÁvilaMendoza2020Molecular) José Ávila-Mendoza, Arasakumar Subramani, Christopher J. Sifuentes, and Robert J. Denver. Molecular mechanisms for krüppel-like factor 13 actions in hippocampal neurons. Molecular Neurobiology, 57(9):3785–3802, June 2020. URL: http://dx.doi.org/10.1007/s12035-020-01971-w, doi:10.1007/s12035-020-01971-w. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12035-020-01971-w)

[10. (Simmen2023Krüppellike) Frank A. Simmen, Iad Alhallak, and Rosalia C. M. Simmen. Krüppel-like factor-9 and krüppel-like factor-13: highly related, multi-functional, transcriptional repressors and activators of oncogenesis. Cancers, 15(23):5667, November 2023. URL: http://dx.doi.org/10.3390/cancers15235667, doi:10.3390/cancers15235667. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15235667)

[11. (Wang2018Transcription) Qiang Wang, Ruixian Peng, Boshi Wang, Jifeng Wang, Wandong Yu, Yongzhong Liu, and Guowei Shi. Transcription factor klf13 inhibits akt activation and suppresses the growth of prostate carcinoma cells. Cancer Biomarkers, 22(3):533–541, September 2018. URL: http://dx.doi.org/10.3233/cbm-181196, doi:10.3233/cbm-181196. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.3233/cbm-181196)